⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118899 | 0.82 | — | — | |
| SCHEMBL6739890 | 0.82 | — | — | |
| Water SCHEMBL29412656 | 0.78 | — | — | |
| SCHEMBL28655470 | 0.77 | FDPS (0.42) | — | |
| SCHEMBL4656428 | 0.77 | FDPS (0.42) | — | |
| SCHEMBL19348712 | 0.77 | FDPS (0.42) | — | |
| SCHEMBL28655469 | 0.77 | FDPS (0.42) | — | |
| SCHEMBL19348711 | 0.77 | FDPS (0.42) | — | |
| Methylene Chloride SCHEMBL1604482 | 0.77 | HTT (0.30) | — | |
| Diethylamine SCHEMBL17396366 | 0.76 | TP53 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-9597326-B2 | Benzonapthyridine compositions and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-03-21 | — | — | US | disclosed |
| US-9517263-B2 | Benzonaphthyridine-containing vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-13 | — | — | US | disclosed |
| US-9408907-B2 | Homogenous suspension of immunopotentiating compounds and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-08-09 | — | — | US | disclosed |
| US-9321721-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-8895577-B2 | Compounds and compositions as TLR activity modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-11-25 | — | — | US | disclosed |
| WO-2014138452-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256819-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-26 | — | — | US | disclosed |
| US-20130122042-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | NOVARTIS AG (CH) | 2013-05-16 | — | — | US | disclosed |
| US-20130101629-A1 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20120263753-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20100215708-A1 | COATING OF DEVICES WITH EFFECTOR COMPOUNDS | NATIONAL SCIENCE FOUNDATION | 2010-08-26 | — | — | US | disclosed |
| EP-1231895-B1 | MODULAR TARGETED LIPOSOMAL DELIVERY SYSTEM | TRANSAVE INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20060172003-A1 | Modular targeted liposomal delivery system | TRANSAVE, INC. (US) | 2006-08-03 | — | — | US | disclosed |
| US-7060291-B1 | Modular targeted liposomal delivery system | TRANSAVE, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1231895-A4 | MODULAR TARGETED LIPOSOMAL DELIVERY SYSTEM | TRANSAVE INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1231895-A1 | MODULAR TARGETED LIPOSOMAL DELIVERY SYSTEM | THE LIPOSOME COMPANY, INC. (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001037807-A1 | MODULAR TARGETED LIPOSOMAL DELIVERY SYSTEM | THE LIPOSOME COMPANY, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-1999043356-A1 | ANTIBIOTIC-LIGAND CONJUGATES AND METHODS OF USE THEREOF | HSC RESEARCH DEVELOPMENT LIMITED PARTNERSHIP (CA) | 1999-09-02 | — | — | WO | disclosed |